Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor.
Ning Jin, Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), W Bensinger, C D Buckner, Finn Bo Petersen(Intermountain Healthcare), D. B. Amos(Florida College), B.J. Still, R. A. Clift(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Roger S. Hill(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gil Segal(Tel Aviv University)
PubMed
January 1, 1987
Cited by 39
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or Lymphoma
|New England Journal of Medicine|1989|687